vs
Side-by-side financial comparison of Sight Sciences, Inc. (SGHT) and Simulations Plus, Inc. (SLP). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $18.4M, roughly 1.1× Simulations Plus, Inc.). Simulations Plus, Inc. runs the higher net margin — 3.7% vs -20.4%, a 24.1% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -2.7%). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs 0.3%).
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity (ADMET) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries. In September 2014, the company acquired Cognigen Corporation, a provider of clinical trial data analysis and consulting services.
SGHT vs SLP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $18.4M |
| Net Profit | $-4.2M | $676.0K |
| Gross Margin | 87.3% | 59.1% |
| Operating Margin | -18.0% | 3.9% |
| Net Margin | -20.4% | 3.7% |
| Revenue YoY | 6.9% | -2.7% |
| Net Profit YoY | 64.9% | 228.2% |
| EPS (diluted) | $-0.07 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | $18.4M | ||
| Q3 25 | $19.9M | $17.5M | ||
| Q2 25 | $19.6M | $20.4M | ||
| Q1 25 | $17.5M | $22.4M | ||
| Q4 24 | $19.1M | $18.9M | ||
| Q3 24 | $20.2M | $18.7M | ||
| Q2 24 | $21.4M | $18.5M | ||
| Q1 24 | $19.3M | $18.3M |
| Q4 25 | $-4.2M | $676.0K | ||
| Q3 25 | $-8.2M | $-681.0K | ||
| Q2 25 | $-11.9M | $-67.3M | ||
| Q1 25 | $-14.2M | $3.1M | ||
| Q4 24 | $-11.8M | $206.0K | ||
| Q3 24 | $-11.1M | $843.0K | ||
| Q2 24 | $-12.3M | $3.1M | ||
| Q1 24 | $-16.3M | $4.0M |
| Q4 25 | 87.3% | 59.1% | ||
| Q3 25 | 86.4% | 56.4% | ||
| Q2 25 | 84.8% | 64.0% | ||
| Q1 25 | 86.2% | 58.5% | ||
| Q4 24 | 86.8% | 54.0% | ||
| Q3 24 | 83.9% | 36.6% | ||
| Q2 24 | 85.8% | 71.5% | ||
| Q1 24 | 85.5% | 72.2% |
| Q4 25 | -18.0% | 3.9% | ||
| Q3 25 | -39.7% | 3.8% | ||
| Q2 25 | -59.6% | -364.5% | ||
| Q1 25 | -79.2% | 12.1% | ||
| Q4 24 | -62.5% | 0.7% | ||
| Q3 24 | -55.7% | -6.2% | ||
| Q2 24 | -59.2% | 10.1% | ||
| Q1 24 | -76.4% | 24.3% |
| Q4 25 | -20.4% | 3.7% | ||
| Q3 25 | -41.0% | -3.9% | ||
| Q2 25 | -61.0% | -330.6% | ||
| Q1 25 | -80.8% | 13.7% | ||
| Q4 24 | -62.1% | 1.1% | ||
| Q3 24 | -54.9% | 4.5% | ||
| Q2 24 | -57.7% | 16.9% | ||
| Q1 24 | -84.4% | 22.0% |
| Q4 25 | $-0.07 | $0.03 | ||
| Q3 25 | $-0.16 | $-0.03 | ||
| Q2 25 | $-0.23 | $-3.35 | ||
| Q1 25 | $-0.28 | $0.15 | ||
| Q4 24 | $-0.23 | $0.01 | ||
| Q3 24 | $-0.22 | $0.04 | ||
| Q2 24 | $-0.25 | $0.15 | ||
| Q1 24 | $-0.33 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.0M | $35.7M |
| Total DebtLower is stronger | $42.4M | — |
| Stockholders' EquityBook value | $63.9M | $127.1M |
| Total Assets | $115.3M | $137.8M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.0M | $35.7M | ||
| Q3 25 | $92.4M | $32.4M | ||
| Q2 25 | $101.5M | $28.4M | ||
| Q1 25 | $108.8M | $21.4M | ||
| Q4 24 | $120.4M | $18.2M | ||
| Q3 24 | $118.6M | $20.3M | ||
| Q2 24 | $118.2M | $119.0M | ||
| Q1 24 | $127.3M | $108.5M |
| Q4 25 | $42.4M | — | ||
| Q3 25 | $42.4M | — | ||
| Q2 25 | $42.4M | — | ||
| Q1 25 | $42.4M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $37.1M | — | ||
| Q2 24 | $35.0M | — | ||
| Q1 24 | $35.0M | — |
| Q4 25 | $63.9M | $127.1M | ||
| Q3 25 | $64.3M | $124.8M | ||
| Q2 25 | $70.0M | $123.8M | ||
| Q1 25 | $77.6M | $189.5M | ||
| Q4 24 | $87.5M | $184.7M | ||
| Q3 24 | $95.0M | $182.4M | ||
| Q2 24 | $101.6M | $180.9M | ||
| Q1 24 | $109.2M | $177.0M |
| Q4 25 | $115.3M | $137.8M | ||
| Q3 25 | $116.3M | $131.9M | ||
| Q2 25 | $122.0M | $134.4M | ||
| Q1 25 | $129.7M | $201.4M | ||
| Q4 24 | $142.8M | $196.9M | ||
| Q3 24 | $143.6M | $196.6M | ||
| Q2 24 | $149.7M | $192.7M | ||
| Q1 24 | $155.6M | $194.0M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $4.2M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -9.7% | — |
| Capex IntensityCapex / Revenue | 0.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 6.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.8M | $4.2M | ||
| Q3 25 | $-8.7M | $5.6M | ||
| Q2 25 | $-7.5M | $8.1M | ||
| Q1 25 | $-11.6M | $5.7M | ||
| Q4 24 | $-3.5M | $-1.3M | ||
| Q3 24 | $362.0K | $1.7M | ||
| Q2 24 | $-9.5M | $5.7M | ||
| Q1 24 | $-9.8M | $5.8M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $-8.9M | $5.3M | ||
| Q2 25 | $-7.8M | $7.8M | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | $-3.6M | $-1.4M | ||
| Q3 24 | $311.0K | $1.6M | ||
| Q2 24 | $-9.5M | $5.6M | ||
| Q1 24 | $-9.9M | $5.4M |
| Q4 25 | -9.7% | — | ||
| Q3 25 | -44.7% | 30.5% | ||
| Q2 25 | -39.6% | 38.5% | ||
| Q1 25 | — | 25.0% | ||
| Q4 24 | -18.9% | -7.2% | ||
| Q3 24 | 1.5% | 8.8% | ||
| Q2 24 | -44.7% | 30.0% | ||
| Q1 24 | -51.4% | 29.4% |
| Q4 25 | 0.8% | 0.0% | ||
| Q3 25 | 0.9% | 1.5% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.7% | 0.5% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.4% | 0.6% | ||
| Q1 24 | 0.6% | 2.4% |
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.84× | ||
| Q4 24 | — | -6.18× | ||
| Q3 24 | — | 1.97× | ||
| Q2 24 | — | 1.81× | ||
| Q1 24 | — | 1.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
SLP
| Services Segment | $9.5M | 52% |
| Development | $7.2M | 39% |
| Discovery | $1.3M | 7% |
